Home
MLYS
MLYS News

Latest Mineralys Therapeutics Inc. (MLYS) News on June 21, 2025

MT Newswires

4 days ago

Mineralys Phase 2 Trial of Hypertension, Kidney Disease Drug Meets Primary Endpoint; Shares Up Pre-Bell

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

GlobeNewswire

4 days ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

MT Newswires

10 days ago

Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target

Mineralys announces late-breaking presentation of data from Launch-HTN trial

TipRanks

25 days ago

Mineralys announces late-breaking presentation of data from Launch-HTN trial

Mineralys reports outcomes from trial of lorundrostat for hypertension

Clinical Trials Arena

a month ago

Mineralys reports outcomes from trial of lorundrostat for hypertension

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

GlobeNewswire

a month ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going

Zacks

a month ago

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

GlobeNewswire

a month ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy

Zacks

a month ago

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy

Thomson Reuters StreetEvents

a month ago

Q1 2025 Mineralys Therapeutics Inc Earnings Call

GuruFocus.com

a month ago

Mineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

MT Newswires

a month ago

Mineralys Therapeutics Q1 GAAP Loss Widens

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire

a month ago

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

GlobeNewswire

a month ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

GlobeNewswire

2 months ago

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

GlobeNewswire

2 months ago

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns

Simply Wall St.

2 months ago

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns

MT Newswires

3 months ago

Mineralys Therapeutics Insider Sold Shares Worth $879,008, According to a Recent SEC Filing

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

GlobeNewswire

3 months ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March

Insider Monkey

3 months ago

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

GlobeNewswire

3 months ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?

Insider Monkey

3 months ago

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

GlobeNewswire

3 months ago

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

MT Newswires

3 months ago

Mineralys Therapeutics Insider Bought Shares Worth $8,100,000, According to a Recent SEC Filing

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

GlobeNewswire

3 months ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

MT Newswires

3 months ago

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

MT Newswires

3 months ago

Mineralys Therapeutics Prices $175 Million Share Offering

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

GlobeNewswire

3 months ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

MT Newswires

3 months ago

Mineralys Therapeutics Launches $250 Million Public Offering of Shares

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire

3 months ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires

3 months ago

Top Midday Gainers

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Benzinga

3 months ago

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Mineralys’s stock soars as hypertension pill scores in two pivotal trials

Clinical Trials Arena

3 months ago

Mineralys’s stock soars as hypertension pill scores in two pivotal trials

MT Newswires

3 months ago

Mineralys Therapeutics Says Lorundrostat Met Trial Endpoints for Treating Hypertension; Shares Up Pre-Bell

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

GlobeNewswire

3 months ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

GlobeNewswire

3 months ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Mineralys Therapeutics Inc Earnings Call

GuruFocus.com

4 months ago

Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ...

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

4 months ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

GlobeNewswire

5 months ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

MT Newswires

5 months ago

Mineralys Completes Enrollment in Mid-Stage Hypertension Trial

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

GlobeNewswire

5 months ago

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials

TipRanks

5 months ago

Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

GlobeNewswire

5 months ago

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Mineralys Therapeutics Announces Q3 2024 Results and Updates

TipRanks

7 months ago

Mineralys Therapeutics Announces Q3 2024 Results and Updates

Thomson Reuters StreetEvents

7 months ago

Q3 2024 Mineralys Therapeutics Inc Earnings Call

MT Newswires

7 months ago

Mineralys Therapeutics Q3 Net Loss Widens

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

7 months ago

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

8 months ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

GlobeNewswire

8 months ago

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

GlobeNewswire

8 months ago

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

GlobeNewswire

8 months ago

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Simply Wall St.

8 months ago

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

GlobeNewswire

9 months ago

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

GlobeNewswire

10 months ago

Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

10 months ago

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

GlobeNewswire

a year ago

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares

GuruFocus.com

a year ago

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares

Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares

GuruFocus.com

a year ago

Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares

MT Newswires

a year ago

HC Wainwright Initiates Mineralys Therapeutics at Buy Rating With $30 Price Target

Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)

GuruFocus.com

a year ago

Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)

MT Newswires

a year ago

Mineralys Therapeutics Insider Sold Shares Worth $592,022, According to a Recent SEC Filing

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares

GuruFocus.com

a year ago

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

GlobeNewswire

a year ago

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)

GuruFocus.com

a year ago

Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)

MT Newswires

a year ago

Mineralys Therapeutics Insider Sold Shares Worth $1,252,718, According to a Recent SEC Filing

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?

Simply Wall St.

a year ago

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Investor's Business Daily

a year ago

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Business Wire

a year ago

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

Investor's Business Daily

a year ago

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

EnviroGold Global Closes First Tranche of Private Placement

GlobeNewswire

a year ago

EnviroGold Global Closes First Tranche of Private Placement

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

GuruFocus.com

a year ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

How markets digested hot jobs print: Top takeaways

Yahoo Finance Video

a year ago

How markets digested hot jobs print: Top takeaways

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

PR Newswire

a year ago

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire

a year ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

a year ago

Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript

We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth

Simply Wall St.

a year ago

We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

GlobeNewswire

a year ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

GlobeNewswire

a year ago

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks

TipRanks

a year ago

Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript

GuruFocus.com

a year ago

Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

GlobeNewswire

a year ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

Mineralys Therapeutics Announces $120 Million Private Placement Financing

GlobeNewswire

a year ago

Mineralys Therapeutics Announces $120 Million Private Placement Financing

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Editas Medicine to Participate in Upcoming Investor Conferences

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

GlobeNewswire

a year ago

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

Investors in ATN International (NASDAQ:ATNI) have unfortunately lost 45% over the last five years

Simply Wall St.

a year ago

Investors in ATN International (NASDAQ:ATNI) have unfortunately lost 45% over the last five years

Covenant Logistics Group, Inc. (NASDAQ:CVLG) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Covenant Logistics Group, Inc. (NASDAQ:CVLG) Q4 2023 Earnings Call Transcript

Share on Social Networks: